1. Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis. Neurology. 2014;83(3):278. https://doi.org/10.1212/WNL.0000000000000560.
2. U.S. Food and Drug Administration. Mitoxantrone (novantrone) prescribing information. 2012. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019297s035lbl.pdf. Accessed 24 June 2021.
3. U.S. Food and Drug Administration. OCREVUS (ocrelizumab) prescribing information. 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761053lbl.pdf. Accessed 24 June 2021.
4. U.S. Food and Drug Administration. MAYZENT® (siponimod) Prescribing Information. 2019. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209884s000lbl.pdf. Accessed 24 June 2021.
5. U.S. Food and Drug Administration. Vumerity (diroximel fumarate) prescribing information. 2019. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211855s000lbl.pdf. Accessed 24 June 2021.